Inloggen

Login
 
Wachtwoord vergeten?

Aandeel Novacyt PSE:ALNOV, FR0010397232

  • 8,010 25 feb 2021 11:17
  • +0,050 (+0,63%) Dagrange 7,910 - 8,180
  • 195.782 Gem. (3M) 1,7M

Novacyt de volgende biotech raket!

54.373 Posts
Pagina: «« 1 ... 2381 2382 2383 2384 2385 ... 2719 »» | Laatste | Omlaag ↓
  1. forum rang 6 Louis7 22 januari 2021 07:36
    The Biden-Harris plan to beat COVID-19

    ..Ensure all Americans have access to regular, reliable, and free testing.

    • Double the number of drive-through testing sites.

    • Invest in next-generation testing, including at home tests and instant tests, so we can scale up our testing capacity by orders of magnitude.

    • Stand up a Pandemic Testing Board like Roosevelt’s War Production Board. It’s how we produced tanks, planes, uniforms, and supplies in record time, and it’s how we will produce and distribute tens of millions of tests.

    www.whitehouse.gov/priorities/covid-19/
  2. forum rang 6 Galapapositief 22 januari 2021 08:20
    www.nature.com/articles/d41586-020-00...

    Three to 14 weeks after the second jab, the study participants developed several types of antibody, including some that can block SARS-CoV-2 from infecting cells. Some of these neutralizing antibodies were as effective against viruses carrying certain mutations in the spike protein as they were against widespread forms of the virus. But some were only one-third as effective at blocking the mutated variants.

    Some of the mutations that the team tested have been seen in coronavirus variants that were first identified in the United Kingdom, Brazil and South Africa; at least one of these variants is more easily transmitted than other forms of the virus now in wide circulation.
  3. Pensioen planner 22 januari 2021 08:42
    quote:

    Ikkedike schreef op 22 januari 2021 08:32:


    [...]
    zoveel fomo vrijdagen zijn er nog niet geweest


    Het verschil met al die andere vrijdagen hiervoor, is dat de kans enorm groot is dat we volgende week informatie krijgen.
    De resultaten van 2020 zullen dan sowieso gedeeld worden met ons en hopelijk ook nog eens een outlook voor 2021 en verder.

    Het kan niet anders dat ze in 2020 schofterig veel geld verdiend hebben en mijn verwachting is dat 2021 alleen nog maar beter zal zijn. Wat de toekomst na 2021 zal zijn is mij nog niet duidelijk. Naar aanleiding van die informatie beslis ik of ik lang ga of na de resultaten toch wat af ga romen.

    edit:
    Ik snap echt de overweging niet om te verkopen. Mensen die zich ook maar enigzins verdiept hebben in Novacyt weten toch dat ze goud in handen hebben?
    Beste producten, uitbreiding team om nog meer klanten en landen te gaan leveren.

    Mijn koersdoel voor 1 feb zal waarschijnlijk niet gehaald worden, maar ik hoop en verwacht dat we medio maart (dik) boven de 20 staan.

    Fijne dag allemaal,
    Namens PP
  4. Remco S. 22 januari 2021 08:53
    Iedereen bedankt voor zijn feedback/mening over het plaatsen van een stop loss. Dat maakt dit forum ook zo sterk zoals al vaker door anderen gememoreerd! Ik reageerde op de vraag van Burstner wat je zou kunnen doen bij dalende koers bij tegenvallende cijfers. Dit geeft echter niet mijn mening of vertrouwen in het aandeel weer want die is namelijk ultra positief zoals bij meesten onder ons.
  5. forum rang 6 Louis7 22 januari 2021 09:04
    COVID-19 TESTING SECTOR DEMAND SET TO CONTINUE

    AMID VACCINE ROLLOUT

    Amid the continued high demand for testing and staggered vaccine rollout, the diagnostics industry, which was valued in 2020 at $17.2bn-$19.8bn, is set to rise further in 2021

    London 21 January 2021 – The diagnostics sector will continue to see growth in 2021 as demand for COVID-19 testing continues to surge. It has been suggested that to ensure effective disease control, the UK alone would require 120m tests per month. Global demand exceeds supply, providing opportunities for existing diagnostics providers and newcomers alike. The diagnostics sector remains a high-growth area, at a time when most other sectors are experiencing disruptions due to the pandemic.

    These are the findings of finnCap’s new quarterly Life Sciences sector report, ‘Rude Health: COVID-19 Diagnostics’.

    COVID-19 testing is likely to peak in 2021 but will continue to see strong demand into 2022 and beyond as a result of the logistical hurdles in vaccinating the global population as well as the uncertainty around how long vaccine jabs provide immunity and their effectiveness against new COVID strains.

    The report looks at the different types of COVID-19 diagnostic technologies and the companies utilizing them. PCR testing is the most common type of testing, providing the highest levels of accuracy, but carries the downsides of being expensive and requiring experienced professionals, with results that can days to process depending on the lab. Companies offering or developing PCR tests include Novacyt, Yourgene and genedrive.

    Lateral Flow Diagnostics, on the other hand, can provide cheap and rapid results (within 15 minutes) and can be administered without training, but are not as accurate as other technologies. Companies offering/developing COVID-19 lateral flow diagnostics include Avacta, Mologic-Omega Diagnostics and Immunodiagnostic systems. The report also highlights two less well-known processes – the ELISA (enzyme linked immunosorbent assays) being utilised by companies such as EKF Diagnostics and LAMP (loop mediated isothermal amplification) being ultilised by companies such as OptiGene.

    The demand for testing is so high that all processes, regardless of their specific advantages and disadvantages will continue to be needed over a busy 2021. FinnCap highlights AIM listed and private companies, Avacta (AVCT), Novacyte (NCYT), Omega Diagnostics (ODX), genedrive (GDR) and OptiGene among them, and discusses the technologies they have employed and the tests that they have developed or are developing.

    In addition, the report also looks at the performance of the AIM life sciences sector, which outperformed larger-cap and health indices and other sectors in 2020, boosted by COVID-19 testing stocks, which will place it in a strong position for 2021. £1.039bn was raised for the life sciences sector on the AIM Index over 2020, a leap on the £242mn raised over the same period in 2019.

    Arshad Ahad, Research Analyst, Life Sciences, at finnCap, commented: “The COVID-19 diagnostics sector was at the forefront of international attention in 2020 as the primary weapon to fight the pandemic. The encouraging progress on vaccines has prompted fears over the sustainability of this market; however, we believe these fears are unwarranted. We believe the market has yet to peak and will do so in 2021, but will remain strong into 2022 and beyond. Overall, it is likely that COVID-19 will be a part of our lives for years to come and may even be a perpetual presence – and as long as this remains the case, COVID-19 testing will be an important tool for keeping the disease in check and avoiding outbreaks.”

    www.pharmiweb.com/press-release/2021-...
54.373 Posts
Pagina: «« 1 ... 2381 2382 2383 2384 2385 ... 2719 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Novacyt Meer »

Koers 8,010   Verschil +0,05 (+0,63%)
Laag 7,910   Volume 195.782
Hoog 8,180   Gem. Volume 1.734.693
25 feb 2021 11:17
label premium

KOPEN OF VERKOPEN?

Het laatste advies leest u als IEX Premium-lid

Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by Infront. Crypto data by Crypto Compare